|
Circulating tumor cells (CTCs) dynamics after CDK4/6i for hormone-receptor positive (HR+) metastatic breast cancer (MBC): A biomarker analysis of the PACE randomized phase II study. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - Menarini Silicon Biosystems |
|
|
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Debiopharm Group (Inst); Ipsen (Inst); Tersera; Tolmar |
Research Funding - AstraZeneca (Inst); Bayer (Inst); bioTheranostics (Inst); Bristol-Myers Squibb (Inst); Debiopharm Group (Inst); Ipsen (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche (Inst); TerSera (Inst) |
|
|
Consulting or Advisory Role - Agendia; Amgen; Daiichi Sankyo/Astra Zeneca; Eisai; Genentech/Roche; Gilead Sciences; Hologic/Biotheranostics; Lilly; Merck; Novartis; Pfizer; Puma Biotechnology; Sanofi; Sermonix Pharmaceuticals; Stemline Therapeutics |
Travel, Accommodations, Expenses - Agendia; Amgen; AstraZeneca; bioTheranostics; Daiichi Sankyo/Lilly; Eisai; Genentech/Roche; Lilly; Merck; Novartis; Pfizer; Puma Biotechnology; Sanofi; Seagen |
|
|
Honoraria - Guardant Health; PlusOne Health |
Consulting or Advisory Role - Agendia; AstraZeneca; Athenex; Bayer; Biovica; Gilead Sciences; Lilly; Novartis; Olaris; Pfizer; Sanofi; Seagen; Tempus |
Research Funding - Pfizer (Inst); Puma Biotechnology (Inst) |
Patents, Royalties, Other Intellectual Property - UpToDate: Authorship - served as a co-author on the subject of endocrine therapy for metastatic breast cancer and receive compensation as an author, less than a few hundred dollars a year. It does not affect my patient care or research. |
Travel, Accommodations, Expenses - SABCS; Total Health Conferencing |
|
|
Consulting or Advisory Role - Pfizer (I) |
Research Funding - Calithera Biosciences (Inst); Genentech (Inst); Inivata/NeoGenomics (Inst); Novartis (Inst); Pfizer (Inst) |
|
|
Honoraria - Medscape; Total Health Conferencing |
Consulting or Advisory Role - AstraZeneca; Curio Science; Genentech; GlaxoSmithKline; Novartis; SeaGen |
Research Funding - Pfizer; Seagen |
Travel, Accommodations, Expenses - Pfizer; Puma Biotechnology; Total Health Conferencing |
|
|
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb/Celgene; Celcuity; Genentech/Roche; Merck |
Research Funding - alphamab (Inst); Astex Pharmaceuticals (Inst); British Biotech (Inst); CytomX Therapeutics (Inst); Pfizer (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Amgen Astellas BioPharma (I) |
Consulting or Advisory Role - AstraZeneca; Gilead Sciences; GlaxoSmithKline; Merck; Novartis; Pfizer; Sanofi |
Research Funding - Bristol-Myers Squibb (Inst); Gilead Sciences; Merck (Inst); Novartis; Novartis (Inst) |
Patents, Royalties, Other Intellectual Property - UpToDate |
|
|
|
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca |
Research Funding - Agendia |
|
|
|
Consulting or Advisory Role - Pfizer |
Research Funding - Pfizer |
Expert Testimony - Williams and Connolly |
|
|
|
Stock and Other Ownership Interests - Pfizer |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - 4D Pharma; AstraZeneca; Athenex; BeyondSpring Pharmaceuticals; Blueprint Medicines; Bristol-Myers Squibb; Certara Inc; Chugai Pharma; CytomX Therapeutics; Daiichi Sankyo; Eisai; Ellipses Pharma; G1 Therapeutics; Genentech; Immunomedics/Gilead; Infinity Pharmaceuticals; Kyowa Hakko Kirin; Lilly; Merck; Mersana; NanoString Technologies; Nektar; Novartis; Odonate Therapeutics; OncoPep; OncoSec; OncXerna Therapeutics; Paxman; Pfizer; Puma Biotechnology; Reveal Genomics; Samsung Bioepis; Sanofi; Seagen; Zentalis; Zymeworks |
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cyclacel (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Lilly (Inst); Merck (Inst); NanoString Technologies (Inst); Nektar (Inst); Novartis (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Sanofi (Inst); Seagen (Inst) |
|
|
|
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Celcuity; Lilly; Menarini; Olaris; Sermonix Pharmaceuticals; Syantra |
Research Funding - Angle; AstraZeneca; Lilly; Menarini Silicon Biosystems; Merck |
|
|
Consulting or Advisory Role - AstraZeneca; Diaccurate; Gilead Sciences; Lilly; Novartis |